無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界における鬱スクリーニング市場の予測

Global Depression Screening Market Research Report - Forecast to 2023

発行 Market Research Future 商品コード 605164
出版日 ページ情報 英文 101 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.67円で換算しております。
Back to Top
世界における鬱スクリーニング市場の予測 Global Depression Screening Market Research Report - Forecast to 2023
出版日: 2017年12月17日 ページ情報: 英文 101 Pages
概要

当レポートでは、世界の鬱スクリーニング市場について調査し、市場の概要とセグメント別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 レポートのプロローグ

第2章 イントロダクション

第3章 調査方法

第4章 市場動向

  • イントロダクション
  • 促進因子
  • 阻害因子

第5章 市場力分析

  • ポーターズファイブフォース分析
  • バリューチェーン分析

第6章 鬱タイプ別市場

  • イントロダクション
  • 心配症
  • 気分障害
  • 鬱病
  • 双極性障害
  • 精神疾患
  • 摂食障害

第7章 診断別市場

  • イントロダクション
  • 精神検査
  • 試験所検査
  • 鬱スクリーニング検査

第8章 治療別市場

  • イントロダクション
  • 投薬
  • 脳刺激治療
  • 薬物乱用治療

第9章 エンドユーザー別市場

  • イントロダクション
  • 病院・診療所
  • 医療研究センター
  • 学術機関

第10章 地域別市場

  • イントロダクション
  • 南北アメリカ
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ

第11章 競合環境

第12章 企業プロファイル

  • Allergan
  • Eli Lilly
  • Novartis AG.
  • Alkermes
  • Bristol-Myers Squibb Company
  • Pfizer

図表

目次

Introduction

Depression and mental health are the leading cause of disability and ill health across the globe. According to the latest estimations from (World Health Organization) WHO, more than 300 million people are now living having depression with an increase of more than 18% between 2005 and 2015. Depression is a kind of mental condition that causes individuals to experience depressed mood, loss of interest, feelings of low self-worth, disturbed sleep or appetite, low energy, and poor concentration. An individual who is suffering from depression experiences intense emotions of anxiety, hopelessness, negativity and helplessness

The market for depression screening by disease type is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, eating disorders and other mental and behavioral & disorders, in which the anxiety market accounted for the largest market share in 2016 due to growing social and environmental variations, and changing lifestyle among the working class across the globe.

The depression screening market is further segmented into diagnosis. These diagnosis are further segmented into psychological test, lab tests, depression screening tests and others. Global depression screening market by diagnosis is expected to reach USD 1,648.98 million by 2023.

Further, the market is segmented on the basis of treatment, which includes medications, brain-stimulation treatments, substance abuse treatment and others. Medications is one of the main treatment for the depression screening market.

Additionally, the market is further segmented on the basis of end user and is bifurcated into hospitals & clinics, medical research centers, academic institutes and others. Out of which hospitals & clinics holds the largest market share among the all the end users.

On the basis of region the market is segmented into America, Europe, Asia-Pacific and Middle East and Africa. Globally Americas holds the largest market share in 2016 due to various factors such as availability advanced diagnostic and treatment, funding for research, increasing number of patients with mental illness and related disorders.

Key Players

Some of the key players in this market are Alkermes (Republic of Ireland), ALLERGAN (Republic of Ireland), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Novartis AG (Switzerland), Otsuka Holdings Co.,Ltd. (Japan), Pfizer Inc. (US), and others.

Study objectives

  • To provide insights about factors influencing and affecting the market growth
  • To provide historical and forecast revenue of the market segments and sub-segments with respect to countries
  • To provide historical and forecast revenue of the market segments based on disease type, diagnosis, end user and regions for the global depression screening market
  • To provide strategic profiling of key players in the market, and comprehensively analysing their market share, core competencies, and drawing a competitive landscape for the market
  • To provide economical factors that influences the global depression screening market
  • To provide detailed analysis of the value chain and supply chain of the global depression screening market

Target Audience

  • Pharmaceutical and Biotech Industries
  • Potential Investors
  • Medical Research Institutes
  • Key Executive (CEO and COO) and Strategy Growth Manager
  • Research Companies

Key Findings

  • Global market for depression screening is majorly dominated by six companies namely Pfizer, Eli Lilly, Allergan, Alkermes, AstraZeneca, Novartis, Bristol-Myers Squibb Company and Others. Eli Lilly takes about 26% of the total market
  • On the basis of level of treatment antidepressants is the fastest growing market
  • Currently, anxiety is leading the market by disease type as anxiety disorders are the most common of all the mental disorders and affects nearly 30% of adults at some point in their lives.
  • The market is growing with an equitable pace of 6.20% annually. Growing emergence of digital health technologies in mental health, rising prevalence of mental disorders across the globe, new focus area in the care continuum has up surged the growth of the market

The reports also covers regional analysis

  • Americas
    • U.S.
    • Canada
    • South America
  • Europe
    • Germany
    • France
    • U.K
    • Italy
    • Spain
    • Rest of Western Europe
    • Eastern Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • Middle East
    • Africa

Table of Contents

1 Report Prologue 12

2 Market Introduction 16

  • 2.1 Scope of Study 16
  • 2.2 Research Objective 16
  • 2.3 Assumptions & Limitations 16
    • 2.3.1 Assumptions 16
    • 2.3.2 Limitations 16

3 Research Methodology 17

  • 3.1 Primary Research Methodology 18
  • 3.2 Secondary Research Methodology 19
  • 3.3 Market Share Analysis 20
  • 3.4 Trade Analysis 20
  • 3.5 Market Pricing Approach 20

4 Market Dynamics 21

  • 4.1 Introduction 21
  • 4.2 Drivers 22
    • 4.2.1 Emergence of digital health technologies in mental health

        (Impact weightage-45%) 22

    • 4.2.2 Growing prevalence of mental disorders around the globe

        (Impact weightage-30%) 23

    • 4.2.3 New focus areas in the care continuum are prevention and recovery

        (Impact weightage-25%) 24

  • 4.3 Restraints 25
    • 4.3.1 Low public awareness of mental disorders and treatments in emerging nations (Impact weightage-55%) 25
    • 4.3.2 Cultural Stigma preventing the market growth (Impact weightage-45%) 26

5 Market Factor Analysis 27

  • 5.1 Porter's Five Forces Model 27
    • 5.1.1 Bargaining Power of Suppliers 28
    • 5.1.2 Bargaining Power of Buyers 28
    • 5.1.3 Threat of New Entrants 28
    • 5.1.4 Threat of Substitutes 28
    • 5.1.5 Intensity of Rivalry 28
  • 5.2 Value Chain Analysis 29

6 Global Depression Screening Market, By Disease Type 30

  • 6.1 Introduction 30
  • 6.2 Anxiety 32
  • 6.3 Mood Disorders 32
  • 6.4 Depression 33
  • 6.5 Bipolar Disorders 33
  • 6.6 Psychotic Disorders 34
  • 6.7 Eating Disorders 34

7 Global Depression Screening Market, By Diagnosis 35

  • 7.1 Introduction 35
  • 7.2 Psychological Test 36
  • 7.3 Lab Tests 37
  • 7.4 Depression Screening Tests 37

8 Global Depression Screening Market, By Treatment 38

  • 8.1 Introduction 38
  • 8.2 Medication 40
  • 8.3 Brain-Stimulation Treatments 40
  • 8.4 Substance Abuse Treatment 41

9 Global Depression Screening Market, By End User 42

  • 9.1 Introduction 42
  • 9.2 Hospitals & Clinics 43
  • 9.3 Medical Research Centers 43
  • 9.4 Academic Institutes 44

10 Global Depression Screening Market, By Region 45

  • 10.1 Introduction 45
  • 10.2 Americas 46
    • 10.2.1 U.S. 49
    • 10.2.2 Canada 51
    • 10.2.3 South America 53
  • 10.3 Europe 55
    • 10.3.1 Germany 58
    • 10.3.2 France 60
    • 10.3.3 UK 62
    • 10.3.4 Italy 64
    • 10.3.5 Spain 66
    • 10.3.6 Rest of Western Europe 68
    • 10.3.7 Eastern Europe 70
  • 10.4 Asia Pacific 72
    • 10.4.1 Japan 75
    • 10.4.2 China 77
    • 10.4.3 India 79
    • 10.4.4 Australia 81
    • 10.4.5 Republic of Korea 83
    • 10.4.6 Rest of Asia Pacific 85
  • 10.5 Middle East & Africa 87
    • 10.5.1 Middle East 90
    • 10.5.2 Africa 92

11 Company Share Analysis 94

12 Company Profiles: Top 7 Players 95

  • 12.1 Allergan 95
    • 12.1.1 Company Overview 95
    • 12.1.2 Financials 95
    • 12.1.3 Products 95
    • 12.1.4 Strategy 95
    • 12.1.5 Key Developments 95
  • 12.2 Eli Lilly 96
    • 12.2.1 Company Overview 96
    • 12.2.2 Financials 96
    • 12.2.3 Products 96
    • 12.2.4 Strategy 96
    • 12.2.5 Key Developments 96
  • 12.3 Novartis AG. 97
    • 12.3.1 Company Overview 97
    • 12.3.2 Financials 97
    • 12.3.3 Products 97
    • 12.3.4 Strategy 97
    • 12.3.5 Key Developments 97
  • 12.4 Alkermes 98
    • 12.4.1 Company Overview 98
    • 12.4.2 Financials 98
    • 12.4.3 Products 98
    • 12.4.4 Strategy 98
    • 12.4.5 Key Developments 98
  • 12.5 Bristol-Myers Squibb Company 99
    • 12.5.1 Company Overview 99
    • 12.5.2 Financials 99
    • 12.5.3 Products 99
    • 12.5.4 Strategy 99
    • 12.5.5 Key Developments 99
  • 12.6 Pfizer 100
    • 12.6.1 Company Overview 100
    • 12.6.2 Financials 100
    • 12.6.3 Products 100
    • 12.6.4 Strategy 100
    • 12.6.5 Key Developments 100

List of Tables

  • TABLE 1 PRIMARY INTERVIEWS 18
  • TABLE 2 GLOBAL DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 31
  • TABLE 3 GLOBAL DEPRESSION SCREENING MARKET FOR ANXIETY, BY REGION, 2014-2023 (USD MILLION) 32
  • TABLE 4 GLOBAL DEPRESSION SCREENING MARKET FOR MOOD DISORDERS, BY REGION, 2014-2023 (USD MILLION) 32
  • TABLE 5 GLOBAL DEPRESSION SCREENING MARKET FOR DEPRESSION, BY REGION, 2014-2023 (USD MILLION) 33
  • TABLE 6 GLOBAL DEPRESSION SCREENING MARKET FOR BIPOLAR DISORDERS, BY REGION, 2014-2023 (USD MILLION) 33
  • TABLE 7 GLOBAL DEPRESSION SCREENING MARKET FOR PSYCHOTIC DISORDERS, BY REGION, 2014-2023 (USD MILLION) 34
  • TABLE 8 GLOBAL DEPRESSION SCREENING MARKET FOR EATING DISORDERS, BY REGION, 2014-2023 (USD MILLION) 34
  • TABLE 9 GLOBAL DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 35
  • TABLE 10 GLOBAL DEPRESSION SCREENING MARKET FOR PSYCHOLOGICAL TEST, BY REGION, 2014-2023 (USD MILLION) 36
  • TABLE 11 GLOBAL DEPRESSION SCREENING MARKET FOR LAB TESTS, BY REGION, 2014-2023 (USD MILLION) 37
  • TABLE 12 GLOBAL DEPRESSION SCREENING MARKET FOR DEPRESSION SCREENING TESTS, BY REGION, 2014-2023 (USD MILLION) 37
  • TABLE 13 GLOBAL DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 39
  • TABLE 14 GLOBAL DEPRESSION SCREENING MARKET FOR MEDICATION, BY REGION, 2014-2023 (USD MILLION) 40
  • TABLE 15 GLOBAL DEPRESSION SCREENING MARKET FOR BRAIN-STIMULATION TREATMENTS, BY REGION, 2014-2023 (USD MILLION) 40
  • TABLE 16 GLOBAL DEPRESSION SCREENING MARKET FOR SUBSTANCE ABUSE TREATMENT, BY REGION, 2014-2023 (USD MILLION) 41
  • TABLE 17 GLOBAL DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 42
  • TABLE 18 GLOBAL DEPRESSION SCREENING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2014-2023 (USD MILLION) 43
  • TABLE 19 GLOBAL DEPRESSION SCREENING MARKET FOR MEDICAL RESEARCH CENTERS, BY REGION, 2014-2023 (USD MILLION) 43
  • TABLE 20 GLOBAL DEPRESSION SCREENING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2014-2023 (USD MILLION) 44
  • TABLE 21 GLOBAL DEPRESSION SCREENING MARKET, BY REGION, 2014-2023 (USD MILLION) 45
  • TABLE 22 AMERICAS DEPRESSION SCREENING MARKET, BY COUNTRY, 2014-2023 (USD MILLION) 46
  • TABLE 23 AMERICAS DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 47
  • TABLE 24 AMERICAS DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 47
  • TABLE 25 AMERICAS DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 48
  • TABLE 26 AMERICAS DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 48
  • TABLE 27 U.S. DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 49
  • TABLE 28 U.S. DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 49
  • TABLE 29 U.S. DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 50
  • TABLE 30 U.S. DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 50
  • TABLE 31 CANADA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 51
  • TABLE 32 CANADA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 51
  • TABLE 33 CANADA DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 52
  • TABLE 34 CANADA DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 52
  • TABLE 35 SOUTH AMERICA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 53
  • TABLE 36 SOUTH AMERICA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 53
  • TABLE 37 SOUTH AMERICA DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 54
  • TABLE 38 SOUTH AMERICA DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 54
  • TABLE 39 EUROPE DEPRESSION SCREENING MARKET, BY COUNTRY, 2014-2023 (USD MILLION) 55
  • TABLE 40 EUROPE DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 56
  • TABLE 41 EUROPE DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 56
  • TABLE 42 EUROPE DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 57
  • TABLE 43 EUROPE DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 57
  • TABLE 44 GERMANY DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 58
  • TABLE 45 GERMANY DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 58
  • TABLE 46 GERMANY DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 59
  • TABLE 47 GERMANY DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 59
  • TABLE 48 FRANCE DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 60
  • TABLE 49 FRANCE DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 60
  • TABLE 50 FRANCE DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 61
  • TABLE 51 FRANCE DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 61
  • TABLE 52 UK DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 62
  • TABLE 53 UK DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 62
  • TABLE 54 UK DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 63
  • TABLE 55 UK DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 63
  • TABLE 56 ITALY DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 64
  • TABLE 57 ITALY DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 64
  • TABLE 58 ITALY DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 65
  • TABLE 59 ITALY DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 65
  • TABLE 60 SPAIN DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 66
  • TABLE 61 SPAIN DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 66
  • TABLE 62 SPAIN DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 67
  • TABLE 63 SPAIN DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 67
  • TABLE 64 REST OF WESTERN EUROPE DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 68
  • TABLE 65 REST OF WESTERN EUROPE DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 68
  • TABLE 66 REST OF WESTERN EUROPE DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 69
  • TABLE 67 REST OF WESTERN EUROPE DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 69
  • TABLE 68 EASTERN EUROPE DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 70
  • TABLE 69 EASTERN EUROPE DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 70
  • TABLE 70 EASTERN EUROPE DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 71
  • TABLE 71 EASTERN EUROPE DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 71
  • TABLE 72 ASIA PACIFIC DEPRESSION SCREENING MARKET, BY COUNTRY, 2014-2023 (USD MILLION) 72
  • TABLE 73 ASIA PACIFIC DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 73
  • TABLE 74 ASIA PACIFIC DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 73
  • TABLE 75 ASIA PACIFIC DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 74
  • TABLE 76 ASIA PACIFIC DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 74
  • TABLE 77 JAPAN DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 75
  • TABLE 78 JAPAN DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 75
  • TABLE 79 JAPAN DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 76
  • TABLE 80 JAPAN DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 76
  • TABLE 81 CHINA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 77
  • TABLE 82 CHINA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 77
  • TABLE 83 CHINA DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 78
  • TABLE 84 CHINA DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 78
  • TABLE 85 INDIA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 79
  • TABLE 86 INDIA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 79
  • TABLE 87 INDIA DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 80
  • TABLE 88 INDIA DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 80
  • TABLE 89 AUSTRALIA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 81
  • TABLE 90 AUSTRALIA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 81
  • TABLE 91 AUSTRALIA DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 82
  • TABLE 92 AUSTRALIA DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 82
  • TABLE 93 REPUBLIC OF KOREA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 83
  • TABLE 94 REPUBLIC OF KOREA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 83
  • TABLE 95 REPUBLIC OF KOREA DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 84
  • TABLE 96 REPUBLIC OF KOREA DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 84
  • TABLE 97 REST OF ASIA PACIFIC DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 85
  • TABLE 98 REST OF ASIA PACIFIC DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 85
  • TABLE 99 REST OF ASIA PACIFIC DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 86
  • TABLE 100 REST OF ASIA PACIFIC DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 86
  • TABLE 101 MIDDLE EAST & AFRICA DEPRESSION SCREENING MARKET, BY COUNTRY, 2014-2023 (USD MILLION) 87
  • TABLE 102 MIDDLE EAST & AFRICA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 88
  • TABLE 103 MIDDLE EAST & AFRICA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 88
  • TABLE 104 MIDDLE EAST & AFRICA DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 89
  • TABLE 105 MIDDLE EAST & AFRICA DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 89
  • TABLE 106 MIDDLE EAST DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 90
  • TABLE 107 MIDDLE EAST DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 90
  • TABLE 108 MIDDLE EAST DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 91
  • TABLE 109 MIDDLE EAST DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 91
  • TABLE 110 AFRICA DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2014-2023 (USD MILLION) 92
  • TABLE 111 AFRICA DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION) 92
  • TABLE 112 AFRICA DEPRESSION SCREENING MARKET, BY TREATMENT, 2014-2023 (USD MILLION) 93
  • TABLE 113 AFRICA DEPRESSION SCREENING MARKET, BY END USER, 2014-2023 (USD MILLION) 93

List of Figures

  • FIGURE 1 GLOBAL DEPRESSION SCREENING MARKET SHARE, BY DISEASE TYPE 2016 (%) 13
  • FIGURE 2 GLOBAL DEPRESSION SCREENING MARKET SHARE, BY DIAGNOSIS, 2016 (%) 13
  • FIGURE 3 GLOBAL DEPRESSION SCREENING MARKET SHARE, BY TREATMENT, 2016 (%) 14
  • FIGURE 4 GLOBAL DEPRESSION SCREENING MARKET, BY REGION, 2016 (%) 15
  • FIGURE 5 RESEARCH METHODOLOGY 17
  • FIGURE 6 PORTERS FIVE FORCES MODEL 27
  • FIGURE 7 VALUE CHAIN: DEPRESSION SCREENING MARKET 29
  • FIGURE 8 GLOBAL DEPRESSION SCREENING MARKET, BY DISEASE TYPE, 2016 & 2023 (USD MILLION) 31
  • FIGURE 9 GLOBAL DEPRESSION SCREENING MARKET, BY DIAGNOSIS, 2016 & 2023 (USD MILLION) 36
  • FIGURE 10 GLOBAL DEPRESSION SCREENING MARKET, BY TREATMENT, 2016 & 2023 (USD MILLION) 39
  • FIGURE 11 GLOBAL DEPRESSION SCREENING MARKET, BY END USER, 2016 & 2023 (USD MILLION) 42
  • FIGURE 12 AMERICAS DEPRESSION SCREENING MARKET, BY COUNTRY, 2016 (%) 46
  • FIGURE 13 EUROPE DEPRESSION SCREENING MARKET, BY COUNTRY, 2016 (%) 55
  • FIGURE 14 ASIA PACIFIC DEPRESSION SCREENING MARKET, BY COUNTRY, 2016 (%) 72
  • FIGURE 15 MIDDLE EAST & AFRICA DEPRESSION SCREENING MARKET, BY COUNTRY, 2016 (%) 87
  • FIGURE 16 GLOBAL DERESSION SCREENING MARKET: COMPANY SHARE ANALYSIS 94
Back to Top